Vertex Pharmaceuticals has made significant progress in treating cystic fibrosis, with a portfolio of drugs and drug combinations that can now treat 90% of patients. The company is also focusing on diversifying its pipeline to include therapies for other diseases, such as pain and type 1 diabetes. Vertex is developing non-opioid drugs for pain treatment, with a particular focus on blocking sodium channels in peripheral nerves. In addition, the company is working on cell therapy for type 1 diabetes, including a program using CRISPR technology to potentially offer a curative therapy without the need for immunosuppressants. Vertex is known for its innovative approach to treating diseases and aims to continue investing in new therapies across different therapeutic areas.
Source link